Progentec Diagnostics, Inc.

By launching first-in-market biomarker tests and developing digital biomarkers for the continuous monitoring of disease, we support clinicians in their effort to provide exceptional care. Our technologies will empower clinician decision making and ensure that patients are able to be active participants in their care. Measuring multiple sclerosis disease activity with a blood test. Tracking multiple sclerosis disease progression with remotely-administered cognitive tests. The company is collaborating with a number of research institutions and individuals around the world engaged in bringing the latest technological innovations to the field of diagnostics.